ImmunityBio (IBRX) Free Cash Flow Growth (5y) (2019 - 2026)

ImmunityBio (IBRX) Free Cash Flow Growth (5y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,320.50 Bn 66,320.21 Bn -
2 Nanobiotix 1,933.82 Bn 1,933.76 Bn -
3 Akari Therapeutics 1,022.34 Bn 1,022.34 Bn -
4 BeOne Medicines 472.93 Bn 468.14 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.22 Bn 114.98 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.96 Bn 61.21 Bn 3.31 Bn
7 Belite Bio 62.66 Bn 62.66 Bn -
8 Argenx Se 56.07 Bn 50.89 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.60 Bn 34.59 Bn 959.66 Mn
10 ImmunityBio 7.22 Bn 6.84 Bn 43.97 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -3.38%
Dec 31, 2025 -4.93%
Sep 30, 2025 -12.69%
Jun 30, 2025 -11.29%
Mar 31, 2025 -22.24%
Dec 31, 2024 5.15%
Sep 30, 2024 -39.89%
Jun 30, 2024 -41.27%
Mar 31, 2024 -52.62%
Dec 31, 2023 -44.87%
Sep 30, 2023 -30.82%
Jun 30, 2023 -32.87%
Mar 31, 2023 -38.32%
Dec 31, 2022 -51.71%
Sep 30, 2022 -57.00%
Jun 30, 2022 -68.24%
Mar 31, 2022 -38.72%
Dec 31, 2021 -45.98%
Sep 30, 2021 -47.67%
Jun 30, 2021 -56.54%